Autobahn Therapeutics

Edit info

Founded: 2017

Location: San Diego, CA

Employee range: 11 - 50

Clinical stage: Clin1

Therapy area: Depression

Drug types: NEU, PSY

Lead product: ABX-002

Funding: $32.7M Sep 2022; $76M B Jun 2020

Investors: ARCH Venture Partners, Cowen Healthcare Investments, BVF Partners L.P., Biogen, Bristol Myers Squibb, Pfizer Ventures, Invus, Section 32, Samsara BioCapital, Alexandria Venture Investments, GT Healthcare

autobahntx.com

linkedin.com

job board

Drug notes:

Also Clin0 affective disorders; ABX-003 Clin0 undisclosed; S1P RD undisclosed

About:

Autobahn Therapeutics is developing regenerative medicines to treat central nervous system (CNS) disorders. Due to the high failure rate in CNS drug development Autobahn is taking a unique approach. This involves combining deep knowledge of underlying disease mechanisms and chemical manufacturing with precision medicine to develop successful therapies, whereby the most effective drugs are matched to the right patient. Autobahn’s brain-targeting chemistry platform creates orally administered small molecule prodrugs with tunable ratios of central vs. peripheral exposure allowing drug distribution profiles to be matched to disease pathophysiology. By understanding human biology, Autobahn is developing a pipeline of transformative small molecule therapies for CNS disorders.

Jobs:

Main

Contact: recruit@workinbiotech.com